Abstract
Clinical management protocols for COVID-19 are evolving rapidly as more information about the epidemiology and pathophysiological changes in COVID-19 become available. However, no definite treatment of COVID-19 has been found till date. The COVID-19 convalescent plasma (CCP) therapy has emerged as an important investigational therapy in the management of COVID-19 patients. Additionally, the regulatory agencies, in particular, the Indian blood transfusion council must release some interim recommendations for the blood centres on the CCP blood donor eligibility criteria after COVID-19 vaccination. More clinical trials are needed to know the efficacy of the CCP harvested from COVID-19 recovered individuals who have been vaccinated against those COVID-19 recovered individuals who are not vaccinated to understand the vaccine impact on the IgG titres of anti-SARS-CoV-2 antibodies.
Keywords: Blood centre; Blood donors; COVID-19; Deferral; Pandemic; Vaccine impact.
【저자키워드】 COVID-19, pandemic, Blood donors, Vaccine impact, Blood centre, Deferral, 【초록키워드】 Treatment, convalescent plasma, IgG, Efficacy, clinical trial, therapy, Epidemiology, anti-SARS-CoV-2 antibodies, COVID-19 vaccination, clinical, management, eligibility criteria, information, COVID-19 patients, Blood, Donor, CCP, individual, titre, regulatory agencies, recommendation, changes in, the vaccine, management protocol, pathophysiological, 【제목키워드】 convalescent plasma, Donor, criteria,